Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 2, 2012, Pages 139-144

  Ecke, Thorsten H ^a   Bartel, Peter ^a   Hallmann, Steffen ^a   Koch, Stefan ^a   Ruttloff, Jürgen ^a   Cammann, Henning ^b   Lein, Michael ^b,c   Schrader, Mark ^b   Miller, Kurt ^b   Stephan, Carsten ^b  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Berlin Institute for Urologic Research   (Germany)

Author keywords

Artificial neural network; External validation; Prostate biopsy; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; ARTIFICIAL NEURAL NETWORK; ASSAY; CANCER DIAGNOSIS; CANCER PROGNOSIS; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BERLIN; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 84857647678     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.12.009     Document Type: Article

References (37)

1. Hodge K.K., McNeal J.E., Terris M.K., et al. Random systematic vs. directed ultrasound guided transrectal biopsies of the prostate. J Urol 1989, 142:71-74.
2. Stricker H.J., Ruddock L.J., Wan J., et al. Detection of non-palpable prostate cancer. A mathematical and laboratory model. Br J Urol 1993, 71:43-46.
3. Naughton C.K., Smith D.S., Humphrey P.A., et al. Clinical and pathologic tumor characteristics of the number of biopsy cores: A retrospective study. Urology 1998, 52:808-813.
4. Levine M.A., Ittman M., Melamed J., et al. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998, 159:471-475.
5. Partin A.W., Oesterling J.E. Clinical use of prostatic specific antigen: Update 1994. J Urol 1994, 152:1358-1368.
6. Polascik T.J., Oesterling J.E., Partin A.W. Prostate specific antigen: A decade of discovery-what we have learned and where we are going. J Urol 1999, 162:293-306.
7. Hudson M.A., Bahnson R.R., Catalona W.J. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989, 142:1011-1017.
8. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909-916.
9. Lee C.T., Scardino P.T. Percent free prostate-specific antigen for first-time prostate biopsy. Urology 2001, 57:594-598.
10. Stephan C., Lein M., Jung K., et al. Can prostate specific antigen derivates reduce the frequency of unnecessary prostate biopsies?. J Urol 1997, 157:1371. [Letter].
11. Garzotto M., Hudson R.G., Peters L., et al. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤10 ng/ml. Cancer 2003, 98:1417-1422.
12. Karakiewicz P.I., Benayoun S., Kattan M.W., et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination, and serum prostate specific antigen. J Urol 2005, 173:1930-1934.
13. Eastham J.A., May R., Robertson J.L., et al. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology 1999, 54:709-712.
14. Djavan B., Remzi M., Zlotta A., et al. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002, 20:921-929.
15. Stephan C., Cammann H., Semjonow A., et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002, 48:1279-1287.
16. Finne P., Finne R., Auvinen A., et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perception network. Urology 2000, 56:418-422.
17. Bababian R.J., Fritsche H., Ayala A., et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ml. Urology 2000, 56:1000-1006.
18. Horninger W., Bartsch G., Snow P.B., et al. The problem of cutoff levels in a screened population. Cancer 2001, 91:1667-1672.
19. Montie J.E., Wei J.T. Artificial neural networks for prostate carcinoma risk assessment. Cancer 2001, 91:1647-1652.
20. Stephan C., Jung K., Cammann H., et al. An artificial neural network considerably improves the diagnostic power of percent free prostate specific antigen in prostate cancer diagnosis-results of a 5 year prospective investigation. Int J Cancer 2002, 99:466-473.
21. Stephan C., Cammann H., Meyer H.A., et al. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett 2007, 249:18-29.
22. Stephan C., Cammann H., Meyer H.A., et al. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics. BJU Int 2008, 102:799-805.
23. Stephan C., Klaas M., Müller C., et al. Interchangeability of measurements of total and free prostate-specific antigen in serum with five frequently used assay combinations: An update. Clin Chem 2006, 52:59-64.
24. Ecke T.H., Gunia S., Bartel P., et al. Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaire. Urol Oncol 2008, 26:474-478.
25. American Joint Committee on Cancer staging manual 2002, Springer, New York. 6th ed.
26. Gleason D.F. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992, 23:273-279.
27. Jung K., Stephan C., Lein M., et al. Receiver-operating characteristics as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms-what has to be considered?. Prostate 2001, 46:307-310.
28. Kairisto V., Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests-GrapfROC for Windows. Scand J Clin Lab Invest 1995, 55(Suppl 222):43-60.
29. Stephan C., Jung K., Lein M., et al. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000, 9:1133-1147.
30. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995, 274:1214-1220.
31. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998, 279:1542-1547.
32. Partin A.W., Catalona W.J., Southwick P.C., et al. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996, 48:55-61.
33. Snow P.B., Smith D.S., Catalona W.J. Artificial neural networks in the diagnosis and prognosis of prostate cancer: A pilot study. J Urol 1994, 152:1923-1926.
34. Chun F.K.H., Graefen M., Briganti A., et al. Initial biopsy outcome prediction-head-to-head comparison of a logistic regression-based nomogram vs. artificial neural network. Eur Urol 2007, 51:1236-1243.
35. Karakiewicz P.I., Bazinet M., Aprikian A.G., et al. Outcome of sextant biopsy according to gland volume. Urology 1997, 49:55-59.
36. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 2005, 48:546-551.
37. Bostwick D.G., Meiers I. Prostate biopsy and optimization of cancer yield. Eur Urol 2006, 49:415-417.